<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-XQTJ7K73/95d68d90-7fb6-477c-9a0f-18039d1c2cc4/HTML"><dcterms:extent>48 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-XQTJ7K73/1832de4f-7f87-4a13-932b-e5b18e0cfe7b/PDF"><dcterms:extent>226 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-XQTJ7K73/6a8c49da-2b89-4709-a45d-055eea95afc1/TEXT"><dcterms:extent>40 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="2005-2025"><edm:begin xml:lang="en">2005</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:DOC-XQTJ7K73"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN" /><dcterms:issued>2009</dcterms:issued><dc:creator>Žmitek, Janko</dc:creator><dc:creator>Žmitek, Katja</dc:creator><dc:format xml:lang="sl">številka:3</dc:format><dc:format xml:lang="sl">letnik:60</dc:format><dc:format xml:lang="sl">8 strani</dc:format><dc:format xml:lang="sl">str. 150-157</dc:format><dc:identifier>ISSN:0014-8229</dc:identifier><dc:identifier>COBISSID:33506565</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-XQTJ7K73</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko farmacevtsko društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Farmacevtski vestnik</dcterms:isPartOf><dc:subject xml:lang="sl">biodostopnost</dc:subject><dc:subject xml:lang="sl">koencim Q10</dc:subject><dc:subject xml:lang="sl">ubikinon</dc:subject><dcterms:temporal rdf:resource="2005-2025" /><dc:title xml:lang="sl">Koencim Q10 kot prehransko dopolnilo in zdravilo| Coenzyme Q10 as a dietary supplement and drug|</dc:title><dc:description xml:lang="sl">Coenzyme Q10 is a lipophilic compound playing an important role in the mitochondrial respiratory chain, where it acts as an electron carrier and as acarrier of proton transfer across membranes. It is also well known for its antioxidant properties. In the body CoQ10 mostly has an endogenous origin and is only partly derived by food. The biological role of CoQ10 is built on its redox equilibrium and continuous transformation between (oxidised) ubiquinone and (reduced) ubiquinol forms. Its function in the body is not affected by theform in which it is consumed. A decline in CoQ10 levels can be observed with increasing age, especially in the most active organs, while the beneficial effect of supplementation has been observed in many medical conditions. Due to its physical properties CoQ10 is very poorly absorbed from the gastrointestinal tract. Oil suspensions (soft-gel capsules) of ubiquinone and later ubiquionol represent the first important steps in increasing the bioavailability, while a further breakthrough was achieved with the development of water-soluble forms. An overview of CoQ10 products available onthe Slovenian market is presented</dc:description><dc:description xml:lang="sl">Koencim Q10 (CoQ10) ima nenadomestljivo vlogo prenašalca elektronov med kompleksi mitohondrijske dihalne verige ter aktivnega nosilca protonov prek notranje mitohondrijske membrane, s oeimer sodeluje v procesu nastajanja gradienta protonov in sinteze ATP. CoQ10 je hkrati tudi edini endogeni maščobotopni antioksidant v telesu. Del ga zaužijemo tudi s hrano. Njegova biološka vloga temelji na redoks ravnotežju med (oksidirano) ubikinonsko in (reducirano) ubikinolno obliko, med katerima neprestano prehaja. Redoks stanje zaužitega CoQ10 (ubikinon / ubikinol) ne vpliva na njegovo funkcijo v telesu. Študije kažejo, da se koncentracije celokupnega CoQ10 v najaktivnejših telesnih organih s staranjem zmanjšujejo, raziskovalci pa so pokazali tudi pozitiven prispevek dodajanja CoQ10 pri razliČenih zdravstvenih stanjih. Ker se zaradi svojih fizikalnih lastnosti tako ubikinon kot ubikinol zelo slabo absorbirata iz prebavnega trakta, je potrebno posebno pozornost posvečati biodostopnosti proizvodov. Prvi veoeji korak za povečevanje biodostopnosti CoQ10 predstavlja razvoj oljnih suspenzij (mehkih kapsul) z ubikinonom in kasneje ubikinolom, nadaljnjega pa razvoj vodotopnih oblik CoQ10. Predstavljen je tudi pregled izdelkov s CoQ10 na slovenskem tržišču</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:DOC-XQTJ7K73"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:DOC-XQTJ7K73" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:DOC-XQTJ7K73/1832de4f-7f87-4a13-932b-e5b18e0cfe7b/PDF" /><edm:rights rdf:resource="http://rightsstatements.org/vocab/InC/1.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko farmacevtsko društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:DOC-XQTJ7K73/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:DOC-XQTJ7K73" /></ore:Aggregation></rdf:RDF>